Sanofi licenses infectious disease assets to Evotec

18 June 2018
2019_biotech_test_vial_discovery_big

German biotech firm Evotec (EVT: Xetra) has signed a deal to in-license more than 10 infectious disease (ID) assets from French drug major Sanofi (Euronext: SAN).

Evotec will also licence-in the majority of Sanofi's ID research portfolio and initiatives and will receive 60 million euros ($70 million) upfront from the Paris-based company along with additional, significant long-term funding to ensure the progression of the anti-infectives portfolio.

"Evotec will have created the highest qualified translational footprint in infectious disease research globally"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology